BNET Industries
Market Cap:$93.2M
Last Fiscal Year Sales:$842.0K
- Public
- US
Dow Jones Description
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in Phase 3 clinical development. One of these Phase 3 drug candidates, Dyloject(TM), is currently under review for Marketing Authorization Application (MAA) approval in Europe. Previous clinical trials have demonstrated its safety and rapid onset of action.
President
Daniel B. CarrNumber of Employees 40
Contact Information
125 Cambridge Park Drive
Cambridge, Massachusetts 02140
(617) 349-4500
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Javelin Pharma JAV Posts Q3 Loss of 11c, Misses Views
-
Javelin Pharmaceuticals: Pain for Pleasure
News & Analysis
Filter by
javelin pharmaceuticals inc. - All News and Analysis
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions Your first question comes from Gary Nachman – Leerink Swann. Gary Nachman – Leerink Swann Marty, on the Dyloject filing, what are you including in the NDA in terms of a rense program? Could you elaborate a little bit on...
Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Javelin Pharmaceuticals, Inc. JAV Q2 2009 Earnings Call August 11, 2009 8:30 am ET
Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions. We’ll take our first question from Gary Nachman - Leerink Swann. Gary Nachman - Leerink Swann First question on the Ereska data; Marty, what did you mean that the outcome could change in the future after you examine all aspects of the data,...
Javelin Pharmaceuticals: Pain for Pleasure
By guest author Nicholas DeCesare, a highly respected investor and journalist within the biopharma realm. Take one look at a chart of Javelin Pharmaceuticals JAV over the past six months and you will see a stock that has doubled in price but still sits only around $2.00 per...
Javelin Pharma's Late-Stage Pipeline Pain
Mike Havrilla submits: Javelin Pharma JAV is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject injectable diclofenac with Therabel Pharma to market the drug in Europe, where it is...
Javelin Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions. We will take our first question from Gary Nachman with Leerink Swann. Gary Nachman - Leerink Swann Hi, good morning. Marty, first what exactly are you looking for the Dyloject observational study? How long are patients actually being tracked, and do you...
Javelin Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator instructions We’ll go to Edmund Kim with JP Morgan. Edmund Kim – JP Morgan Hi, thanks for the additional commentary regarding the Dyloject launch in the UK. I have a few questions. One, the – NDA filing for Dyloject now appears to...
Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject™ at the 12th World Congress on Pain
GLASGOW, Scotland -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal Phase 3 study of Dyloject([TM]). At the 12th World Congress on Pain, held in Glasgow, Scotland. Dyloject was launched in...
Javelin Pharmaceuticals Inc Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. We will take our first question from Edmund Kim with JPMorgan. Edmund Kim - JPMorgan Hi, great. Thanks for taking the questions. You talked about 25% penetration among 190 gold accounts. At what percentage, do you start to then shift your attention more toward increasing...
Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer Session Operator Thank you. Operator Instructions. And we will take our first question from Adam Greene from JPMorgan. Adam Greene - JPMorgan Thanks. Good morning everyone. Martin Driscoll Good morning, Adam. Adam Greene - JPMorgan Marty can you talk about your decision to do...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Daniel B. Carr | President |
| Belinda Coote | Chief Executive |
| David B. Bernstein | General Counsel & Chief Intellectual Property Officer |
| Stephen J. Tulipano | Cfo |
| Curtis Wright | Vice President, Risk Mgmt & Regulatory Affairs |
| Frederick E. Pierce | Vice President, Ir |
| Mark Matthews | Vice President, Commercial Affairs |
| Michael Moshman | Vice President, Clinical & Commercial Manufacturing |
| Michael T. Sheckler | Vice President, Business Dev |
| Brian Pratt | Executive Director |
| Anne Garbutt | Director of Consultancies and Programme Management |
| Phil Dines | Publishing Manager |
| Susie Prince | Project Manager |
| Bruce Britton | Independent Consultant |
| Fran Deans | Consultant |
| Hugh Goyder | Economist |
| John Cammack | Independent Trainer and Consultant |
| John Hailey | Independent Consultant |
| Katie Wright-Revolledo | Senior Researcher |
| Kulnara Djamankulova | Community Development Advisor |
| Lucy Earle | Researcher |
| Roberta O'Neill | Administrator |
| Derek Roebuck | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Anne Coles | Vice Chair of the Trustees |
| Douglas G. Watson | Board of Directors |
| Fred H. Mermelstein | Board of Directors |
| Georg Nebgen | Board of Directors |
| Jackie M. Clegg | Board of Directors |
| Janet Townsend | Board of Directors |
| Martin J. Driscoll | Board of Directors |
| Neil W. Flanzraich | Board of Directors |
| Peter Poore | Board Member |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | President | Current |
| Innovative Drug Delivery Systems, Inc. | Cmo | Current |
| Javelin Pharmaceuticals, Inc. | Vice Chairman | Current |
| Javelin Pharmaceuticals, Inc. | Chief Medical Officer | Former |
| Javelin Pharmaceuticals, Inc. | Board of Directors | Former |
Belinda Coote has been Chief Executive of Medical Aid for Palestinians (MAP) since 2002. MAP is a UK charity, which grant assists NGOs and governments in Gaza, West Bank, Israel and Lebanon to improve the health of Palestinians and their host communities. Before joining MAP, Belinda worked for Oxfam in a career spanning 18 years and a range of different posts. As a policy advisor she specialised in international trade, published widely and undertook a number of advocacy campaigns. As a programme manager she was Oxfam?s representative first in Nepal and then in Bangladesh and then worked as regional manager for South Asia. She became a Director in the International Division and spent some time working as Regional Director for Southern Africa.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Chief Executive | Current |
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| International Division | Regional Director | Former |
| International Division | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | General Counsel & Chief Intellectual Property Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Cfo | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice President, Risk Mgmt & Regulatory Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice President, Ir | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice President, Commercial Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice President, Clinical & Commercial Manufacturing | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice President, Business Dev | Current |
Brian is one of the founding members of INTRAC and at present is the Executive Director. Brian has worked in development since 1973, initially at the University of Cambridge and in Peru on the Political Economy of Peru. Brian was also a Field Director for OXFAM in the Andean Countries (1977-82), before returning to the UK to develop OXFAM programmes and Departments of Research, Evaluation, Development Policy and Information systems (1982-90). During this period he wrote the OXFAM Field Director's Handbook, was the founding editor of the Development in Practice journal and the Development Guidelines series of seven books. Brian has worked in many countries as a consultant and researcher for NGOs, and multi- and bi-lateral agencies. The primary focus of Brian's publications and consultancies is on strategic policy issues for NGOs and Monitoring and Evaluation (M&E). Brian completed his Ph.D at Cambridge University in 1980, after he graduated from University of Birmingham (B.Sc, Sc.) in 1972.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Executive Director | Current |
| University of Birmingham | Former |
Anne has worked in development since 1983, after a career in the National Health Service. Her first overseas posting was with VSO in Nepal where she trained traditional birth attendants and primary health care workers. Having decided that she wanted to pursue a career in development, she was successful in gaining Overseas Development Assistance (ODA) sponsorship to do a Masters in Community Health at Liverpool University through their Associate Professional Officers Scheme (APOS).
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Director of Consultancies and Programme Management | Current |
| Vso | Former | |
| Liverpool University | Masters In Community Health | Former |
Phil Dines joined INTRAC in July 2006. He is responsible for developing the publishing programme, website maintenance and overseeing the running of the library. Since graduating from Oxford Brookes University in 2001 with a Postgraduate Diploma in Publishing, Phil has worked in a variety of publishing roles. He joins INTRAC from his position as Production Editor in the Higher Education department of Oxford University Press, where he was responsible for the quality, scheduling and budgeting of their textbooks. Prior to this, Phil spent a year travelling through South East Asia and Central America. Phil has a BA in English and American Literature from Manchester University.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Publishing Manager | Current |
| Manchester University | Ba In English and American Literature | Former |
| Oxford Brookes University | Former |
Susie joined INTRAC in January 2005 and was appointed as Project Manager in October 2006. Prior to joining INTRAC, Susie worked both as a teacher and in the children?s educational media sector and more recently for VSO in China. In this role she designed and implemented projects on a number of themes including HIV/AIDS, environment, disability and development education. Susie has both practical and research experience in participatory methodologies and planning, minority cultures, thematic mainstreaming, organisational development and capacity building. Susie has an MA in Development Studies and Education from POLIS, University of Leeds.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Project Manager | Current |
| Javelin Pharmaceuticals, Inc. | Teacher | Former |
| University of Leeds | Ma In Development Studies and Education | Former |
Bruce Britton is an independent consultant and trainer working in the fields of organisational development, organisational learning, capacity building and strategy development. He is also involved in work on child rights and rights-based approaches to development. Bruce has worked in the fields of social and community development since 1976, first as a social worker then as a community worker and for fourteen years with Save the Children in the UK and South Asia as a project manager, staff development specialist and human resource development adviser. Bruce became an independent consultant in 1998, joined a small support network of UK-based consultants called Framework the following year and has been an INTRAC associate since 1999. Bruce has worked at head offices and internationally with a range of development, humanitarian and environmental organisations and networks including BOND, Christian Aid, Save the Children (Denmark, Norway and Sweden), UNHCR, WaterAid, CAFOD, The International Forum for Rural Transport and Development, Tearfund, UNDP, WWF (Scotland, UK and International), Scottish Environment LINK and The Swedish Mission Council. His consultancy work includes strategic reviews, particularly focusing on organisational learning, programme and project reviews and organisational strategy development. He co-facilitates the INTRAC short-course on ?Organisational Development and Change? and has research interests in learning in organisations and network development. Bruce has an MBA from Edinburgh University, a postgraduate BPhil in Social Work from Exeter University and a BSc in Environmental Sciences from the University of East Anglia. He is also a Member of the Chartered Institute of personnel and Development.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Independent Consultant | Current |
| Edinburgh University | Mba | Former |
| University of East Anglia | Bsc In Environmental Sciences | Former |
Fran Deans recently joined the INTRAC research team after having spent the past year working in Rwanda as a consultant. In Rwanda, Fran worked on various projects, including managing and drafting the final report of a focus group research project into Rwandan youth?s attitude to sex and condoms. This work consolidated her experiences working as an intern in the Development DG of the European Commission where she worked largely on HIV/AIDS issues. Fran also has substantial experience working in the field of Roma rights, from working as Programme Officer on a UK-based Roma rights programme to assisting Livia Jaroka MEP in her work on Roma issues. Fran?s social anthropology doctoral thesis is an ethnography of a Hungarian Romany community and an analysis of a community development micro-enterprise scheme, which ends with recommendations for future programmes.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Consultant | Current |
Hugh Goyder originally trained as an economist, but then worked as a UN volunteer in India, before joining Oxfam in 1976. He worked as an Oxfam Country Director, first in India, and subsequently in Ethiopia, where he led Oxfam's response to the 1984 famine. On returning to the UK he worked for Oxfam on evaluation issues, and in 1992 joined Action Aid UK, initially as their Co-ordinator for West & Southern Africa, and later as their first Co-ordinator for Impact Assessment. He became an independent consultant and INTRAC Associate in 1998.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Economist | Current |
John Cammack works as an independent trainer and consultant in financial management. He was Head of International Finance at Oxfam GB and Senior Lecturer in Accounting and Financial Management at Oxford Brookes University. John has worked internationally with a range of relief and development agencies, including the Aga Khan Foundation, Amnesty International, British Overseas NGOs for Development, European Commission, International Federation of Red Cross and Red Crescent Societies, RedR and VSO. He has been an Intrac associate for 12 years. John's training and consultancy work includes financial management for non-specialists, training financial trainers and developing NGO financial communication. He sets financial management in the context of organisational management and international development, making it accessible and practical. His current research interests include the effectiveness of communication between NGO programme and finance staff. John is a qualified accountant and teacher. He has an MBA from Brunel University and an MSc in Development Management from the Open University. www.johncammack.net
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Independent Trainer and Consultant | Current |
| John Cammack | Current | |
| Oxford Brookes University | Senior Lecturer | Former |
| Amnesty International | Former | |
| Redr | Former | |
| Vso | Former | |
| Brunel University | Mba | Former |
| Open University | Msc In Development Management | Former |
John Hailey is an independent consultant and a Visiting Professor at City University?s Cass Business School in London. He has extensive international experience, and has undertaken a range of commissions and consultancies for a wide range of clients, including NGOs, donors, multilaterals and governments, in over thirty-five different countries.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Independent Consultant | Current |
| City University | Visiting Professor | Former |
Katie Wright-Revolledo has recently joined INTRAC as Senior Researcher having worked at the University of Bath since 2001. From 2001-2003 Katie worked at Bath as a researcher on the 'Improving the impact of microfinance on poverty alleviation' Imp-Act programme. She is also an associate of the ESRC research group on ?Wellbeing in Developing Countries? (WeD) at the University of Bath. Last year she won an ESRC fellowship to consolidate her research to date using theoretical sources from Area Studies, Development Studies and Gender Studies to examine the wider social impacts of microfinance. In recent work she has concluded that it is necessary to look beyond the parameters of poverty alleviation interventions such as microfinance to the cultural, political and economic setting in which individuals are embedded. Katie has also published on identity issues in Peru and has an active interest in migration issues.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Senior Researcher | Current |
Kulnara took up the post of Community Development Advisor for Kazakhstan in July 2002. For the previous seven years, Kulnara had worked for UNDP in Kyrgyzstan and then in Kazakhstan in various roles, but most recently as Community and Business development specialist. She has known INTRAC since 1996, when she was a participant of PRA training in Kyrgyzstan. Kulnara has a degree in economics.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Community Development Advisor | Current |
Lucy is currently studying for her PhD at the Development Studies Institute of the London School of Economics and Political Science (LSE), with support from INTRAC through an ESRC collaborative studentship. Her research is focused on the dynamics of the homeless movements in Sao Paulo, Brazil, and the impact of urban social movements on the policy making process. Prior to beginning her doctoral studies in October 2005, Lucy had worked for three years on INTRAC?s research team. During this time she focused primarily on community development and social movements, undertaking extensive fieldwork in Central Asia and Peru. Her work on community development in Central Asia is documented in two INTRAC publications. The study of indigenous social movements in Peru is ongoing, and Lucy will continue to contribute to this research process over the coming years.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Researcher | Current |
Bobbie O?Neill joined INTRAC in June 2001 as Administrator for INTRAC?s DfiD funded Central Asia Programme. In 2003 she took on the additional role of supporting INTRAC?s consultancies team moving permanently to consultancies work in autumn 2004.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Administrator | Current |
Dr. Anne Coles has extensive experience of working on development issues both as a practitioner and as an academic and researcher. Anne was a member of the Research Assessment Exercise (RAE) 2001 sub-panel for Development Studies. Originally trained as a geographer, she has particular interests in public health, nutrition, water supplies, migration, and marginal areas. She worked for ODA/DFID for five years and, as a senior social development adviser, leading on gender issues following the Beijing Conference, she was the UK?s representative on the OECD/DAC Working Party for Gender Equality.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Vice Chair of the Trustees | Current |
Derek Roebuck, MA (Oxon), MCom (VUW) is a solicitor. He is the editor of Arbitration, the Journal of the Chartered Institute of Arbitrators. Derek is Senior Associate Research Fellow at the Institute of Advanced Legal Studies and Guest Professor at the People?s University of China. He was formerly professor of law (comparative law) in Australia, Papua New Guinea and Hong Kong. He has written over forty books on law, legal history and language, including the 7 volume Peking University Press bilingual texts on Hong Kong contract, criminal law and procedure. Recently he has written on the history of dispute resolution: A Miscellany of Disputes (2000), Ancient Greek Arbitration (2001), The Charitable Arbitrator: How to Mediate and Arbitrate in Louis XIV?s France (2002) and Roman Arbitration (2004). He is now working on Early English Arbitration.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Secretary | Current |
| Peking University | Former |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| Javelin Pharmaceuticals, Inc. | Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| Javelin Pharmaceuticals, Inc. | President & Founder | Former |
| Innovative Drug Delivery Systems, Inc. | President | Former |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
Janet Townsend is a Senior Research Investigator at the University of Newcastle, UK. She retired from lecturing in Geography at the University of Durham, UK after 34 years. Janet engages in participatory research with poor women in low-income countries. She is concerned with issues of poverty, power, self-empowerment and the (dangerous) power of academics, particularly those in prosperous countries. For many years, she worked with pioneer colonists in the rainforests of South America, particularly Colombia. Then she engaged in participatory research with the women pioneers, who were enthusiastic about the work of NGOs. This led her to seek to understand the extraordinary growth and dynamism of NGOs today.
| Organization | Position | Status |
|---|---|---|
| University of Newcastle | Investigator | Current |
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board of Directors | Current |
Dr Peter Poore qualified as a doctor at St Bartholomew?s Hospital in London in 1964. He has 30 years experience of health care delivery in many of the world?s poorest countries. He joined Save the Children Fund in 1983 and eventually became senior health adviser responsible for all aspects of the Fund?s work in the health sector. Peter has written and published on health issues and special interests include the quality of primary health care, sustainability of health care delivery systems, health sector reform, refugee health care, reproductive health care, the Expanded Programme on Immunisation, and the impact of HIV/AIDS on all aspects of health and social welfare. He has worked as a consultant for a range of development agencies. He was a core member of the Financing Task Force of the Global Alliance for Vaccines and Immunisation, and the alternate NGO representative for Northern NGOs on the Board of the Global Fund to fight AIDS, TB and Malaria. He is currently a Board member of a number of NGOs, including Health Unlimited, INTRAC, The Malaria Consortium and Evidence for Development. He is on the editorial advisory Board of Health Policy and Planning. He has also recently returned to part-time general practice in the NHS UK. He was awarded OBE in 2001.
| Organization | Position | Status |
|---|---|---|
| Javelin Pharmaceuticals, Inc. | Board Member | Current |
| Health Unlimited | Board Member | Current |
| Global Fund | Board of Directors | Current |
Executive News
-
IP Advocate Enhances Interactive IPAO Forum with New Expert Opinions Section
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

